Rapid lung NGS is enabling clinicians and reducing biomarker testing costs
In this recorded webinar, learn how the Massachusetts General Hospital (MGH) Center for Integrated Diagnostics (CID) has consolidated a legacy single gene testing system into one workflow based on fast and automated next-generation sequencing (NGS) to produce a rapid lung molecular testing program. This workflow allows for a turnaround time (TAT) of 36–72 hours and provides clinicians with a consolidated biomarker report, while significantly reducing complexity, hands on time, and costs in the lab.
Watch the sneak peek below:
View this webinar to:
- Learn from the experiences of a leading cancer center in consolidation NSCLC biomarker testing in to Rapid Lung NGS program
- Understand the positive implications for oncologists and patients with cancer from the oncologist point of view
- Understand how the new consolidated workflow saves time and resources
Speakers:
Lauren Ritterhouse, MD, PhD
Associate Director, Center for Integrated Diagnostics, Massachusetts General Hospital
Assistant Professor, Pathology, Harvard Medical School
Ibiayi Dagogo-Jack, MD
Thoracis Oncologist, Massachusetts General Hospital
Assistant Professor of Medicine, Harvard Medical School
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Please fill out the short form below to view the webinar.